Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000693284 | SCV000821146 | uncertain significance | Primary dilated cardiomyopathy | 2020-06-07 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals with NEBL-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change replaces tyrosine with aspartic acid at codon 719 of the NEBL protein (p.Tyr719Asp). The tyrosine residue is highly conserved and there is a large physicochemical difference between tyrosine and aspartic acid. |
Ambry Genetics | RCV004025149 | SCV002727226 | uncertain significance | not specified | 2024-03-15 | criteria provided, single submitter | clinical testing | The c.2155T>G (p.Y719D) alteration is located in exon 22 (coding exon 22) of the NEBL gene. This alteration results from a T to G substitution at nucleotide position 2155, causing the tyrosine (Y) at amino acid position 719 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |